Deadline For Changing Liposomal Medicine Names Nears in EU
Executive Summary
EU regulators have explained how makers of medicines with liposomal and pegylated liposomal delivery systems must change the names of their products to avoid medication errors.
You may also be interested in...
EU Revises Liposomal Drug Naming Advice
Marketing authorization holders of liposomal drug delivery systems will have to consider elements such as route of administration, medication error reporting or long-established use to assess whether their medicines are prone to medication errors.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.